Drug Trial Radar · NCT05309421
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Sep 19, 2022
Primary completion
Apr 7, 2026
Study completion Apr 7, 2026
Sponsor
- Lead sponsor
- Evaxion Biotech A/SIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
Conditions
- Melanoma Stage IV
- Unresectable Melanoma
Interventions
EVX-01Drug
Investigational drug given in combination with standard of care
Pembrolizumab 25 MG/MLDrug
Standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the best overall response (BOR)Time frame: Measurements at Baseline through study completion (up to 102 weeks)
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
One Clinical Research
Nedlands, Western Australia, Australia
Divisione di Oncologia Medica del Melanoma
Milan, Italy, Italy
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.